The Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP Pancreatitis
Status:
COMPLETED
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, single-blind, parallel controlled clinical study to explore the optimal dose of postoperative indomethacin suppository for the prevention of post-ERCP pancreatitis. The purpose of this study is to explore the optimal dosage of indomethacin suppository for PEP prevention, to study the control effect of indomethacin on hyperamylaseemia, and to further explore the group of patients who benefit most from this therapy.
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University